KalVista Pharmaceuticals (KALV) Receivables - Other (2017)
KalVista Pharmaceuticals recorded quarterly Receivables - Other of $73000.0 in Q3 2017, down 75.42% quarter-over-quarter from $297000.0 in Q2 2017.
KalVista Pharmaceuticals' Receivables - Other history runs 1 years deep, the most recent figure standing at $73000.0 for Q3 2017.
- In Q3 2017, Receivables - Other changed N/A year-over-year to $73000.0; the TTM figure through Jul 2017 stood at $73000.0 (changed N/A YoY), while the FY2017 annual figure was $297000.0, down 16.57% from the prior year.
- Receivables - Other came in at $73000.0 for Q3 2017 at KalVista Pharmaceuticals, down from $297000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $398000.0 in Q1 2017 to a low of $73000.0 in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2017 | 73,000.00 |
| Jul 31, 2017 | 73,000.00 |
| Apr 30, 2017 | 297,000.00 |
| Apr 30, 2017 | 297,000.00 |
| Jan 31, 2017 | 398,000.00 |
| Jan 31, 2017 | 398,000.00 |